Sidarth Radjou’s Post

Weekly Tech+Bio Highlights #5, from our Sunday newsletter: • Roche gains FDA 501(k) clearance for its Digital Pathology Dx system, featuring the VENTANA DP 200 slide scanner and workflow software for digital pathology. • Yonalink completes its largest EHR-to-EDC data transfer pilot, achieving 93% data streaming accuracy across 21 medical centers in the US and Israel. • Enveda Biosciences secures $55M in Series B2 funding, raising its total capital to $230M, with investors including Premji Invest, Microsoft, and Kinnevik. • Iambic Therapeutics' AI platform NeuralPLexer, showcased in Nature Machine Intelligence, surpasses AlphaFold2 in predicting protein-ligand complex structures. They raise $50M for their HER2-positive cancer program. • Insilico Medicine completes Phase IIa patient enrollment in China for INS018_055 for idiopathic pulmonary fibrosis, with results expected late Q4 2024 and a Phase IIb study planned for 2025. • Athos Therapeutics Inc selects Vultr's private cloud and NVIDIA HGX H100 GPUs to enhance its AI drug discovery, integrating multi-omics data from over 25,000 patients. • FDA imposes partial hold on BioNTech/MedLink's antibody-drug conjugate trial after three patient deaths, affecting new enrollments in the Phase I trial for BNT326/YL202. • Google Research and Google DeepMind introduce Tx-LLM, an AI tool for drug discovery and therapeutic development, fine-tuned from Med-PaLM 2, outperforming state-of-the-art models in multiple tasks. • Basecamp Research and Ferruz Laboratory launch ZymCTRL, the first open-source, text-based AI tool for enzyme design. • GNQ Insilico uses its AI-driven platform to create digital twins of human patients and simulate the effects of an infertility drug. For a more in-depth look at these developments and more, check out our full newsletter, link in the comment section.

📢 Hot off the Press In America, as new clinical trials unfold 🗽 With imaging algorithms, bright and bold ⭐ In Japan, they proceed ⛩️ With precision and speed 💪 As new treatments and data take hold! 👨⚕️   Welcome to our collaboration! - Medical Metrics, Inc. & Micron, Inc Read the press release here: https://lnkd.in/gjsxCDZf Learn more about the MMI-Micron Collaboration: https://lnkd.in/g-ExNxXj #MedicalMetrics N Shastry Akella, David Ricciardi, Patrick Newman, Elaine F. Chan, PhD, K. Teal Wurm, Michal Houston, Kim Horn, Sara Minton, Vijay Ramu, Daniel Auger, Summer Jackson, BS, MPH, Kirk Johnson, Chris Vaughn, Rosemary J Shull #Micron Hiroaki Suzuki, Naoyuki Ohira, Takehito Okamoto, Naoki Matsukawa, Ikuko Ito, Yoshito Nakamoto, Kanako Kitahama, Shang-Ming Yeh, Felix Rehnberg medicalmetrics.com microncro.com/en #MMI #Imaging #imagingcorelab #clinicalresearch #clinicalstudies #clinicaltrials #medicalimaging #centralimaging #imagingforclinicaltrials #pharma #medicaldevice #oncology #neurology #cardiovascular #ENT #musculoskeletal #OA #RA

Amyotrophic Lateral Sclerosis (ALS) is a crippling disorder that attacks motor neurons, causing a progressive decline in nerve cells within the spinal cord and brain, ultimately leading to death. Typically, individuals diagnosed with ALS have a life expectancy ranging from two to five years. Currently, there is no cure or means to stop its progression. However, a new drug, FB1006, developed with cutting-edge AI technology, holds promise as a potential treatment for ALS. Led by 4B Technologies, the development of FB1006 has hit a pivotal point with the successful enrollment of 64 participants for a clinical trial at the Third Hospital of Peking University. This trial, under the guidance of Professors Bai Lu and Dongsheng Fan, represents a collaborative effort across academia, industry, research, and clinical medicine to find new treatments for ALS. AI technology has been instrumental in several stages of FB1006's development, from pinpointing therapeutic targets to selecting participants for the trial. Initial research by Insilico Medicine identified 28 possible treatment targets for ALS, facilitated by AI, with three of these targets being associated with drugs already approved for other conditions. Impressively, FB1006 moved from target identification to the start of clinical trials in less than two years, showcasing the power of AI in speeding up the process of drug development. https://lnkd.in/eArjkvUi

Revolutionizing Medical Diagnostics: Fujitsu's New Frontier in Explainable AI In a bold move that could transform genomic medicine and cancer treatment planning, Fujitsu has unveiled its latest innovation in AI technology—Explainable AI. This cutting-edge development not only understands complex data across various formats like text, images, and numbers but also converts this information into knowledge graphs. These graphs significantly enhance the interpretability of large-scale datasets, making crucial medical insights more accessible than ever. In rigorous testing phases, the AI demonstrated high accuracy in classifying lung cancer types and predicting breast cancer patient survival rates, showcasing its potential to support medical professionals with precise diagnostics. Moreover, Fujitsu’s AI does not stop at simply analyzing data; it provides explanations by referencing the analysed data. It is a game changer ensuring transparency and trust in AI-driven medical diagnostics. As Fujitsu prepares to roll out this technology on its Research Portal by the end of fiscal 2024, the implications for healthcare are profound. Medical professionals are on the brink of having a tool that not only augments their expertise but also provides a new level of clarity in treatment planning. This is not just a technological advancement but a leap towards more personalized, efficient, and transparent healthcare. For more details on this groundbreaking technology, read the full press release here. https://lnkd.in/efGX3qRv #artificialintelligence, #lifesciences, #pharmaceutical #innovation

ARZ Business Solutions is proud to announce a pioneering collaboration between ConcertAI and NeoGenomics!🌟 Together, they have introduced a cutting-edge AI software-as-a-service solution for hematology clinical research, known as CTO-H [A](https://lnkd.in/gHtj8Hy5). This solution is designed to enhance research analytics, clinical trial design, and operational optimization in hematology [A](https://lnkd.in/gECG6hWy). 🔍 Key Highlights: - Unmatched Scale and Depth: CTO-H provides an unparalleled view of hematological diseases, featuring a comprehensive database of over 370,000 patient lives [A](https://lnkd.in/gCguyW-C). - Accelerated Innovation: By increasing precision in clinical trial design, this solution aims to reduce development time and foster meaningful biomedical advancements. - Expert Collaboration: NeoGenomics brings extensive expertise in clinical diagnostics, while ConcertAI leads in predictive and generative AI solutions [A](https://lnkd.in/gECG6hWy). Join us in celebrating this milestone in hematology research and stay tuned for more updates! #ARZBusinessSolutions #ConcertAI #NeoGenomics #HematologyResearch #Innovation #ClinicalTrials

It is widely recognized that randomized clinical trials (RCT) are expensive, lengthy, and burdensome on patients. According to some estimates, it takes more than a billion dollars in funding and a decade of work to bring one new medication to market. While there are exciting advances in genomics, patient-centric awareness, decentralized clinical trials, and the application of artificial intelligence (AI), there is a lack of compelling evidence to date that these trends have had a significant impact on the time and cost of the typical oncology clinical trial. Nor have these developments yet had a significant impact on making clinical oncology trials less burdensome on patients.  While the highly regulated nature of the industry is clearly one of the culprits in this respect, other factors such as the industry's reluctance to change, significant data integrity issues and a bias towards incremental improvement are equally noteworthy.

Check out this upcoming webinar with Medidata Solutions to help optimize imaging strategies and support clinical trial outcomes! There will be discussions about implementing robust imaging workflows within data collection processes, enhancing efficiency and effectiveness in clinical trials, overcoming common imaging challenges, and streamlining imaging management. #ClinicalTrials #Oncology #ImagingData #AI #Medidata #Webinar #ClinicalResearch #MedicalImaging #ClinicalData #Diagnostics #SoftwareSolutions #DataSolutions #ClinicalTrialManagement #ClinicalOperations #DigitalHealth

#AI is providing a huge acceleration into #drug R&D processes in particular in oncology 🔬 Current AI #drugdiscovery efforts take an average of two to three years, compared to four to seven years for those without AI. #Clinicaldevelopment timelines using the novel tech run around three to five years, instead of the average seven to nine years without AI In particular, AI has been used for #oncology and #neurology R&D, which reflects the urgency to address critical health issues more quickly As #bigpharma develops AI platforms in-house, it could potentially slow down M&A/deals with AI discovery players. What the article discounts is that big pharma research teams still tend to weigh heavily towards the science vs. AI, continuing to leave opportunities for AI #biotechs to differentiate. https://lnkd.in/d9aCeXVN

Good morning. There has been some interesting news from the clinic and regulators over the past few weeks across biotech and medical devices. Here are some top headlines that we found. 🔔 GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density of amyloid plaque in the brains of people with Alzheimer’s disease. 🔔 As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors as well as some precancerous lesions. 🔔 The FDA has launched a study to examine the potential toxicity of metals that can be found within tampons—a regulated medical device, from the agency’s point of view. 🔔 The orthopedic robotics developer Think Surgical has collected its third FDA clearance in as many months, with a specialized version of its knee replacement system designed to be paired with an implant from Zimmer Biomet. 🔔 Small biotechnology company iTeos Therapeutics could succeed where larger drugmakers have fallen short, should study results it presented Saturday at a cancer research conference hold up in further testing. The results, from a mid-stage clinical trial, show that adding iTeos’ drug to an approved GSK immunotherapy shrank lung tumors in roughly twice as many people as GSK’s therapy alone. 🔔 Drug based on anti-nausea agent reduces Alzheimer's-advancing astrocytes in mice, says Hoth Therapeutics. 🔔 Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data 🔔 Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor. #medicaldevices #medicaltechnology #biotechnology #therapeutics #science #engineering